Rosen Law Firm Scrutinizes Disc Medicine Over Misleading Information
Investors who suffered losses in Disc Medicine, Inc. are being urged to join a potential securities class action investigation. New York-based Rosen Law Firm is evaluating claims that the company disseminated materially misleading business information, following a regulatory setback that triggered a sharp decline in the firm’s stock price.
The investigation centers on the company’s bitopertin program. On February 13, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, effectively denying the approval of its new drug application. Federal regulators cited significant uncertainties in the application that required additional evidence, a disclosure that caused the company's stock to plummet 22% in a single day.
Rosen Law Firm, which specializes in shareholder derivative litigation, is soliciting participants for a prospective class action. Investors who purchased securities during the relevant period may be eligible for compensation under a contingency fee arrangement. Those interested in the inquiry are directed to reach out to attorney Phillip Kim to discuss potential recovery options for their financial losses.
Comments (0)
No comments yet. Be the first!